Advertisement
News
Advertisement

Alexion lands FDA priority review for blood clotting drug target

Wed, 06/01/2011 - 10:33am
Mass High Tech: The Journal of New England Technology

Alexion Pharmaceuticals Inc. has won priority review from the U.S. Food and Drug Administration for its supplemental Biologics License Application for the company’s drug candidate Soliris to treat atypical Hemolytic Uremic Syndrome (aHUS).

Soliris is already FDA approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading